Maymetsi

Metformin Hydrochloride and Sitagliptin, the active ingredient in Maymetsi, is a biguanide and DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of type 2 diabetes mellitus in adult patients when diet and exercise alone are insufficient.

GNH USA supplies Maymetsi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company emphasizes quality assurance and regulatory compliance in all shipments. Maymetsi is manufactured under EU Good Manufacturing Practice standards and is distributed to meet global demand.

Maymetsi, a combination of metformin and sitagliptin, is used in the management of type 2 diabetes mellitus. - Type 2 diabetes mellitus: improves overall glycemic control when diet and exercise are insufficient. - Adjunct to insulin therapy: enhances glucose regulation in patients requiring additional lowering of blood glucose. - Combination therapy: reduces HbA1c levels more effectively than either component alone.

Maymetsi may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea. - Headache: mild to moderate intensity. - Hypoglycemia (when combined with insulin or sulfonylureas): symptoms of low blood sugar.

Serious or Rare Side Effects: - Lactic acidosis: a rare but potentially fatal metabolic complication. - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Hepatic dysfunction: abnormal liver enzymes or hepatitis. - Renal impairment worsening: especially in patients with pre‑existing kidney disease.

Before prescribing Maymetsi, several safety considerations should be evaluated. - Renal function assessment: avoid use in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²). - Hepatic impairment monitoring: use with caution in patients with liver disease. - Risk of lactic acidosis: discontinue if signs of metabolic acidosis appear. - Hypoglycemia vigilance: monitor blood glucose when used with insulin or sulfonylureas. - Pregnancy and lactation: only use if potential benefit justifies potential risk to fetus or infant. - Store below 25°C: keep in the original packaging, protect from moisture and light.

Maymetsi can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure when combined with metformin. - Concomitant use with other DPP‑4 inhibitors: increases risk of adverse effects without added benefit. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise sitagliptin plasma levels.

Moderate Interactions (Monitor Closely): - Insulin or sulfonylureas: increased risk of hypoglycemia. - Diuretics (e.g., furosemide): may affect renal clearance of metformin. - Cimetidine: can raise metformin concentrations.